Acute traumatic brain injury (TBI) is associated with long-term cognitive and behavioral dysfunction. In vivo studies have shown histone deacetylase inhibitors (HDACis) to be neuroprotective following TBI in rodent models. HDACis are intriguing candidates because they are capable of provoking widespread genetic changes and modulation of protein function. By using known HDACis and a unique small-molecule pan-HDACi (LB-205), we investigated the effects and mechanisms associated with HDACi-induced neuroprotection following CNS injury in an astrocyte scratch assay in vitro and a rat TBI model in vivo. We demonstrate the preservation of sufficient expression of nerve growth factor (NGF) and activation of the neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway following HDACi treatment to be crucial in stimulating the survival of CNS cells after TBI. HDACi treatment up-regulated the expression of NGF, phospho-TrkA, phospho-protein kinase B (p-AKT), NF-κB, and B-cell lymphoma 2 (Bcl-2) cell survival factors while down-regulating the expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein apoptosis factors. HDACi treatment also increased the expression of the stem cell biomarker nestin, and decreased the expression of reactive astrocyte biomarker GFAP within damaged tissue following TBI. These findings provide further insight into the mechanisms by which HDACi treatment after TBI is neuroprotective and support the continued study of HDACis following acute TBI.
Acute traumatic brain injury (TBI) is associated with long-term cognitive and behavioral dysfunction. In vivo studies have shown histone deacetylase inhibitors (HDACis) to be neuroprotective following TBI in rodent models. HDACis are intriguing candidates because they are capable of provoking widespread genetic changes and modulation of protein function. By using known HDACis and a unique small-molecule pan-HDACi (LB-205), we investigated the effects and mechanisms associated with HDACi-induced neuroprotection following CNS injury in an astrocyte scratch assay in vitro and a rat TBI model in vivo. We demonstrate the preservation of sufficient expression of nerve growth factor (NGF) and activation of the neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway following HDACi treatment to be crucial in stimulating the survival of CNS cells after TBI. HDACi treatment up-regulated the expression of NGF, phospho-TrkA, phospho-protein kinase B (p-AKT), NF-κB, and B-cell lymphoma 2 (Bcl-2) cell survival factors while down-regulating the expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein apoptosis factors. HDACi treatment also increased the expression of the stem cell biomarker nestin, and decreased the expression of reactive astrocyte biomarker GFAP within damaged tissue following TBI. These findings provide further insight into the mechanisms by which HDACi treatment after TBI is neuroprotective and support the continued study of HDACis following acute TBI.
A cute traumatic brain injury (TBI) is a leading cause of disability and death, and results in reduced quality of life for surviving patients and prolonged economic effects on society (1) . Primary injury occurs at the moment of trauma and is the direct result of shearing, tearing, and stretching of the brain parenchyma affecting neural tissue and blood vessels, and causing immediate contusion, hemorrhage, diffuse axonal injury, and ischemia (2, 3) . TBI brings about cognitive and behavioral dysfunction through a complex sequence of secondary pathologic changes following injury. The mechanisms evolve over time and include excessive neurotransmitter release, mitochondrial dysfunction, increased bloodbrain barrier (BBB) permeability, cerebral edema, inflammation, and seizures, causing cell death and clinical morbidity (4) .
Clinical trials designed to test therapeutic agents aimed at improving residual cerebral function after TBI have not been successful because of the multifactorial nature of the disorder (2, (5) (6) (7) . No pharmacological agent is currently approved for the treatment of acute TBI. The present standard of care consists of maintaining physiologic function by preserving adequate cerebral perfusion and normal intracranial pressure. Histone deacetylase inhibitors (HDACis) are potential candidates for the treatment of TBI. They are capable of inducing widespread alterations in cellular function and protein expression through posttranslational modification of histones, transcriptional factors, and heat shock chaperones (8) (9) (10) .
Several studies have demonstrated HDACis to be effective neuroprotective agents following TBI in rodent models (4, (11) (12) (13) (14) (15) (16) . Administration of HDACis after TBI has been shown to reduce cortical contusion volume and inflammation, induce the expression of genes and proteins involved with cell survival, and improve cognitive and motor outcomes. The precise mechanisms by which HDACis produce these effects remain unclear. We developed an in vitro astrocyte scratch assay to examine the molecular effects associated with the administration of HDACis following mechanical glial cell injury (17) . A TBI rat model was also established to investigate the efficacy of the pan-HDACi LB-205 for the treatment of acute TBI in vivo.
Results

LB-205 Enhances Migration of Astrocytes and Stem Cell Characteristics While Increasing Cell Proliferation Within Injury Repair Zone and
Attenuating Apoptosis in Vitro. LB-205 is a Zn 2+ -dependent paninhibitor of class I and class II HDACs with potent activity and a long half-life (12 h) in vivo (8) . We sought to examine the effect of LB-205 on the injury of astrocytes in vitro. A scratch assay with human fetal astrocytes (HFAs) was used to observe morphological changes that occur during the activation of astrocytes following mechanical injury and subsequent repair with and without HDACi treatment. LB-205 increased the quantity of histones acetyl-H1, H2A.X, acetyl-H3, and acetyl-H4 postscratch (Fig. 1A) , confirming the efficacy of LB-205 treatment during astrocyte scratch.
The growth of astrocytes was observed at 4-h time intervals following scratch. HDACis were administered 4 h postscratch, and the percentage of the injury area filled in was measured. This measurement was performed to evaluate the effect of HDACis on the time needed to repair the wound. LB-205 significantly enhanced the migration of astrocytes and accelerated wound repair more effectively than suberoylanilide hydroxamic acid (SAHA), valproic acid (VPA), or DMSO at 16 h postscratch [12-h posttreatment; repeated-measures two-way ANOVA F (9,18) = 13.77, P < 0.0001; Fig. 1B ]. The expression of biomarkers associated with glial activation was also evaluated. Immunofluorescence staining revealed an increased population of nestin (type-VI intermediate filament protein)-expressing cells at the edges of wounds after treatment with LB-205 compared with untreated scratched cells or scratched cells treated with SAHA or VPA (Fig. 1C) . Nestin is a known marker for neural stem cell and progenitor cell populations within the CNS (17, 18) . Western blot analysis of the expression of nestin 24 h postscratch further confirmed this result Whole-Genome Expression Microarray Analysis in Vitro. Gene-expression profiling has the capability to identify biomarkers and elucidate complex genetic interactions that may play a mechanistic role in the molecular response and outcome following TBI with HDACi modulation (19) . Whole-genome microarray analysis of scratched astrocytes was preformed with untreated samples and samples treated with LB-205. Biological functions and individual gene expressions were filtered for ≥twofold changes in induction. The expression of individual genes related to neural cell survival through the nerve growth factor (NGF) neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway, NGF, NTRK1, AKT, NFKB, and BCL2 were significantly up-regulated [NGF, one-way ANOVA F (2,6) = 29.79, P < 0.0008; NTRK1, one-way ANOVA F (2,6) = 85.57, P < 0.0001; AKT, one-way ANOVA F (2,6) = 79.03, P < 0.0001; NFKB, one-way ANOVA F (2,6) = 53.65, P < 0.0001; BCL2, one-way ANOVA F (2,6) = 81.04, P < 0.0001; Fig. 2D ]. The expression of genes related to the activation of apoptosis through the NGF p75 neurotrophin receptor (NTR) pathway, p75(NTR), JNK, and Bcl-2-associated X protein (BAX) were significantly down-regulated [p75(NTR), one-way ANOVA F (2,6) = 133.9, P < 0.0008; JNK, one-way ANOVA F (2,6) = 15.20, P < 0.0045; BAX, one-way ANOVA F (2,6) = 292.0, P < 0.0001; Fig. 2D ]. (16) . Most of this work has focused primarily on assessing the efficacy of VPA, a class I-specific HDACi with long half-life (8-15 h), although potent pan-HDACis (ITF2357) have also been shown to be efficacious. In considering our in vitro data, it being known that LB-205 possesses potent activity and long half-life (12-h) in vivo, and previous studies used in vivo TBI models for HDACi testing, we sought to develop an appropriate TBI rodent model to test the efficacy of LB-205 and to evaluate its mechanism. The right frontal cortex of rats aged 6 to 8 wk was lesioned by using a cortical impact device. i.p. injections of HDACi were administered 4 h, 24 h, and 48 h after injury. Rats treated with 10 mg/kg of LB-205 performed significantly better at standardized cross-beam balance motor testing 7 d after TBI [n = 10; repeated-measures two-way ANOVA F (6,18) = 101.9, P < 0.0001] than those that were untreated (Fig. 3A) . LB-205 administration was well tolerated by the rats. Histological analysis was performed on post-TBI tissue samples from normal brain, heart, lung, liver, spleen, kidney, and pancreas in rats following LB-205 treatment and demonstrated no organ toxicity in comparison with nontreated rats. Compared with TBI alone, LB-205 treated rats killed 2 wk postinjury demonstrated less scaring and decreased contusion volume upon gross postmortem examination of brain tissues (Fig. 3B) . Pathological analysis revealed enhanced gliosis and increased cellular density with LB-205 treatment following TBI (Fig. 3C ).
LB-205 Blunts Reactive Astrocytosis and Promotes Proliferation of
Cells Expressing Neural Stem Cell Biomarkers in Vivo. Immunofluorescence assays were performed 2 wk postinjury to assess the expression pattern of biomarkers associated with the repair of CNS injury. Expression of GFAP (type-III intermediate filament protein) in LB-205-treated rats was reduced at the sight of injury compared with nontreated rats (Fig. 3D) . The expression of nestin was increased with LB-205 treatment and was most pronounced in proliferative cells adjacent to the site of injury. These results indicate that LB-205 enhanced the molecular repair process in vivo by reducing reactive astrocytosis and stimulating the formation of proliferative cells with stem cell characteristics.
LB-205 Maintains NGF Expression Post-TBI in Vivo and Postscratch in
Vitro. NGF is a member of the neurotrophin superfamily and is known to maintain the survival of neurons during development through stimulation of its high-affinity TrkA receptor (20, 21) .
NGF can also induce cell-mediated death through NGF withdrawal or stimulation of its low-affinity p75(NTR) receptor (21, 22) . The finding of elevated activation of NGF TrkA pathway with whole-genome expression assay in vitro led us to examine lesioned rat brain tissue samples for NGF pathway modulation 1 wk following TBI with and without treatment with LB-205. Expression of NGF and its receptor TrkA were preserved after treatment with LB-205 compared with untreated TBI [NGF, oneway ANOVA F (2,6) = 1,955, P < 0.0001; phospho-TrkA (p-TrkA), one-way ANOVA F (2,6) = 203.1, P < 0.0001; Fig. 4A ]. A prominent increase in p75(NTR) expression was observed following TBI, which was significantly attenuated by treatment with LB-205 [one-way ANOVA F (2,6) = 4794, P < 0.0001; Fig. 4A ]. Increases in phospho-JNK (p-JNK), cleaved caspase 3, and cleaved-poly ADP ribose polymerase (PARP) proapoptotic factors were mitigated after treatment with LB-205 [p-JNK, one-way ANOVA F (2,6) = 235.8, P < 0.0001; caspase 3, one-way ANOVA F (2,6) = 252.2, P < 0.0001; PARP, one-way ANOVA F (2,6) = 29.94, P < 0.0001; Fig. 4B ]. Administration of LB-205 also increased the expression of phospho-protein kinase B (p-AKT), NF-κB, and nuclear receptor co-repressor-1 (NCoR), a known regulator of stem cell development [p-AKT, one-way ANOVA F (2,6) = 4,531, P < 0.0001; NF-κB, one-way ANOVA F (2,6) = 83.29, P < 0.0001; NCoR, one-way ANOVA F (2,6) = 24.57, P < 0.0001; Fig. 4C ]. 
Discussion
Epigenetic mechanisms are important regulators of gene-environment interactions. Histone methylation and acetylation are critically involved in cognitive function and are necessary for maintaining neural plasticity (9) . Rodent models have established that neurons exhibit increased histone acetylation during the process of learning, and hindrance of this process leads to age- dependent memory impairment (23, 24) . It has also been shown that histone-H3 acetylation is reduced following TBI, and that this finding is associated with measurable cognitive dysfunction in rodents (15) . Translating this knowledge has led to the discovery that many human neurodegenerative disorders are also associated with relative decreases in histone acetylation. These findings have formed the basis for exploring the use of HDACis in the treatment of TBI and other forms of CNS injury.
HDACis have been shown to be efficacious in treating TBI in rodent models, with recent work predominately focused on the use of VPA. VPA is an HDACi with additional functionality in its ability to inhibit GABA transamination, reduce NMDAmediated excitation, and block voltage-gated sodium and calcium channels (25) . Rodents treated with VPA post-TBI exhibit improved performance in memory and motor dependent tasks (4). Our results demonstrate that LB-205 similarly improved functional outcome in a rat TBI model. Upon molecular examination in vitro, we found that LB-205 increased histone-H3 acetylation and the expression of Hsp70 while attenuating caspase-3 activation, analogous to the results obtained in studies testing the use of VPA in an ischemic injury rodent model (14) . Furthermore, we demonstrated that LB-205 enhanced astrocyte migration and proliferation within the injury repair zone more than VPA or SAHA. VPA is a drug with known dose-dependent liver toxicity, and has been shown to require supratherapeutic dosing (400 mg/kg) to produce comparative molecular effects and clinical outcomes in rodents (4). LB-205 reduced post-TBI morbidity and enhanced the injury repair response in rats at a safe low therapeutic dose (10 mg/kg).
Here we present that HDACi treatment following TBI preserves NGF expression and TrkA survival pathway activation while attenuating expression of GFAP and inducing expression of nestin in reactive astrocytes, as insight into the mechanisms underlying the improved functional outcomes in rodent models observed with HDACi treatment post-TBI. NGF is a highly conserved neuropeptide and shares homology within different species. It plays an important role in rapid neural apoptosis and axonal guidance during embryogenesis and early development. In adult life, NGF is produced within the cortex, hippocampus, and pituitary gland while also playing an essential role in the survival of basal forebrain cholinergic neurons involved with arousal, attention, memory, and motivation (26) . However, NGF may also play an critical role in the regeneration of injured neurons post-TBI (26) (27) (28) (29) (30) . In addition, increased NGF levels in cerebral spinal fluid following TBI are known to be correlated with improved clinical outcome (31) . NGF expression may be necessary to promote neuron survival and function post-TBI during the injury repair process.
NGF stimulates cell survival or cell death through independent signaling mechanisms (Fig. 5) (21) . When NGF binds to its high-affinity cellular receptor TrkA, it stimulates the p-AKT pathway through PI3K, which, in turn, through NF-κB, induces the transcription of genes responsible for cell survival. Conversely, when NGF binds its low-affinity p75(NTR) caspase activity is induced, and apoptosis is triggered. NGF is elevated within the penumbra in rats following ischemic injury, and might be necessary to prevent low-affinity p75(NTR) receptor activation and neuronal apoptosis (29) . Additionally, neurotrophic factor treatment in rats following TBI has been shown to attenuate reductions in cortical volume and enhance functional recovery following ischemic injury and TBI (28, 30) . We found that LB-205 up-regulated the expression of NGF, p-TrkA, p-AKT, NF-κB, and Bcl-2 cell survival factors, while diminishing the expression of p75(NTR), p-JNK, and BAX apoptosis factors. This result effectively modulated the injury repair process by maintaining a balance of NGF activity in favor of cell survival in vivo and in vitro. Determining the modification of which specific HDAC (s) and histones are responsible for these effects requires further study. It should also be considered that modulation of temporal and spatial patterns of NGF expression after HDACi treatment within in areas of the brain not directly lesioned could affect functional outcomes post-TBI.
Expression of nestin was significantly enhanced by LB-205 in vivo and in vitro within the zone of injury repair, suggesting that increased proliferation of cells with stem cell characteristics might play an important role in enhancing CNS injury repair and preserving neural cell function post-TBI. Expression of GFAP was diminished by LB-205 treatment at 2 wk postinjury and may represent an additional mechanism by which HDACi treatment post-TBI blunts CNS scar formation and significant disruption of the remaining neural network. GFAP, a biomarker of reactive astrocytosis and axonal damage, is elevated in the CSF of patients post-TBI (32) . The hallmark of reactive gliosis following injury is increased GFAP expression and subsequent hypertrophy of astrocyte processes and repression nestin expression (33) . Following scratch injury, GFAP expression is induced in reactive astrocyte populations migrating to fill in and repair the injury zone (17) . Reactive astrocytes therefore play an important role in the acute stage of CNS injury, although they may inhibit neural regeneration and CNS repair with prolonged activation. The specific mechanisms by which expression of nestin is up-regulated and GFAP expression is diminished following HDACi treatment post-TBI require further study. However, NGF is known to stimulate the expression of biomarkers associated with neural stem cell characteristics, and may be responsible for the increased expression of nestin and attenuated GFAP expression observed following treatment with LB-205 (34) .
The complete mechanisms underlying how HDACis modulate the injury repair response in the CNS remain unknown. Gene chip analysis revealed significant up-regulation of noteworthy genes, including HSPA1A, EDN3 and IL6, that were not investigated in depth. Heat shock protein 70, coded for by HSPA1A, a molecular chaperone (protein) also induced after treatment with VPA and ITF2357, is neuroprotective and improves protein salvage by presumably serving to expand the availability of proteins necessary for cell survival following injury (16, 35) . The role of endothelin-3 (EDN3), coded for by EDN3, vasoactive peptide induction following HDACi is less clear. Blocking the EDN3 receptor triggers apoptosis in glioma cancer stem cells and a functional reduction in cell migration (36) . EDN3 therefore may have a role in maintaining cell survival and improving glial cell motility post-TBI. The deficiency of proinflammatory cytokine IL-6, coded for by IL6, in KO mice has been demonstrated to diminish the capacity to cope with brain injury (37) . Furthermore, increased BBB permeability has been shown to be an important mechanism involved with neural cell loss following TBI, although this process likely improves CNS drug delivery (38) . HDACi effects on BBB permeability and other factors mentioned require further study. HDACis likely produce much of their beneficial effects post-TBI by buffering the cellular response to injury. We have established the potential significance of HDACi-mediated preservation of NGF TrkA pathway activation and augmentation of proliferation of nestin-expressing cells with stem cell characteristics post-TBI. We have also shown that LB-205 reduces post-TBI morbidity in rats at lower therapeutic concentrations than VPA, and with no observed toxicity. Our experimental findings support growing evidence for the neuroprotective effects of HDACis and continued research into their use following acute TBI.
Materials and Methods
Animals and in Vivo HDACi Treatment. Animal experiments were approved for use and care of animals under the protocol guidelines of the National Institutes of Health (NIH) Animal Care and Use Committee. Sprague-Dawley rats (aged 6-8-wk, male) were purchased from Harlan Laboratories. Animals were randomized into three groups: sham (n = 6), TBI (n = 6), and TBI treated with LB-205 (n = 8). Animals were subjected to controlled cortical impact TBI as previously described (39) . Briefly, animals were anesthetized with isoflurane (1.5%) in 1:1 oxygen:nitrous oxide gas mixture and placed in a stereotactic device. A 5 × 5-mm craniotomy was placed in the right parietal bone with a handheld trephine. The impactor tip was regulated down to the dural surface, and a penetrating contusion was made over the right frontal cortex at 2.1 to 2.2 mm depth at 5 m/s velocity. The burr hole was covered with a bone flap and sealed with Jet Denture Repair. Following standard postsurgical analgesia, each animal was given buprenorphine at 0.01 to 0.05 mg/kg (i.p. injection). All rats were allowed to recuperate after surgery before return to cages. Animals were observed postsurgery for appropriate incision healing and monitored daily for clinical and behavioral signs. Further details are provided in SI Materials and Methods.
